Therapy Areas: Central Nervous System
Biocept Receives South Korean Patent for Primer-Switch Platform Used to Identify Rare Genetic Mutations, Including Cancer Biomarkers
9 July 2021 - - US-based molecular diagnostic assays and services provider Biocept, Inc. (NASDAQ: BIOC) has been awarded a South Korean Patent for its Primer-Switch technology, which detects rare mutations in circulating tumor DNA (ctDNA) using real-time PCR and associated analysis methods, the company said.

The patent (No. 2252447) is titled Methods for Detecting Nucleic Acid Sequence Variants.

This is the fourth issued patent for the technology, which identifies rare cancer biomarkers found in tissue, blood, and cerebrospinal fluid. Primer-Switch provides a unique method for specifically enriching patient specimens for mutations of interest.

It can be used to enhance the performance and specificity of the PCR method, the most widely used amplification approach for research and clinical diagnostic applications. It also enables the interrogation of fragmented DNA that is often found in biological fluids.

Biocept's core technologies and products are protected by more than 70 issued patents in the US, EU, Australia, China, Japan, and South Korea, as well as other countries.

This includes worldwide patent protection on its highly sensitive methods for detecting cancer biomarkers that are used by physicians for treatment decisions.

Biocept, Inc., develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information to aid in the diagnosis, treatment and monitoring of patients with cancer.

In addition to its broad portfolio of blood-based liquid biopsy tests, the company has developed the CNSide cerebrospinal fluid assay, designed to diagnose cancer that has metastasized to the central nervous system.

Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide RT-PCR-based COVID-19 testing and services to support public health efforts during this unprecedented pandemic.
Login
Username:

Password:


Related Headlines